文献速递血脂与心血管预防

PCSK9通过阻止SNX17介导的LDLR循环促进LDLR降解

PCSK9 Promotes LDLR Degradation by Preventing SNX17-Mediated LDLR Recycling.
PubMed 文献 · Circulation · 2025-03-12

该研究探讨PCSK9介导LDLR降解的分子机制。酸性pH诱导LDLR胞外域构象变化,促进其经胞内域与SNX17结合;PCSK9阻止该构象变化并阻断LDLR与SNX17的相互作用,从而抑制LDLR循环并加速溶酶体降解。破坏LDLR循环的FH序列变异对PCSK9及其抑制剂无反应。

要点

  • PCSK9通过阻断SNX17介导的LDLR循环促进LDLR溶酶体降解
  • 破坏LDLR循环的FH序列变异对PCSK9抑制剂无反应
  • 此类患者需基因诊断及不依赖LDLR的替代药物

核心结论

  • PCSK9通过阻止SNX17介导的LDLR循环来促进LDLR降解。
  • 导致LDLR循环缺陷的FH序列变异患者对PCSK9抑制剂耐药。

研究设计与样本

  • 研究采用体外和体内方法探究PCSK9介导LDLR降解的分子和细胞机制。
  • 在Ldlr敲除小鼠和敲除HuH7细胞中表达含FH序列变异的LDLR,评估其对PCSK9及PCSK9抑制剂的反应。

主要发现

  • 酸性pH诱导LDLR胞外域构象变化,并通过胞内域促进其与SNX17相互作用。
  • 敲低SNX17可废除LDLR循环并导致溶酶体降解加速。
  • PCSK9阻止酸性pH诱导的LDLR构象变化,并阻断LDLR与SNX17的相互作用。
  • 敲低SNX17可废除PCSK9介导的LDLR降解。
  • 任何破坏LDLR循环的FH序列变异,即使能内化LDL,也对PCSK9或PCSK9抑制剂无反应。

临床怎么用

  • 对于PCSK9抑制剂耐药患者,应考虑基因诊断以明确是否存在破坏LDLR循环的FH序列变异。
  • 对存在LDLR循环缺陷的FH患者,需使用不依赖LDLR的替代药物进行治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Low-density lipoprotein (LDL) is internalized into cells mainly through LDLR (LDL receptor)-mediated endocytosis. In an acidic endosome, LDLR is released from LDL and recycles back to the cell surface, whereas LDL is left in the endosome and degraded in the lysosome. Circulating PCSK9 (proprotein convertase subtilisin/kexin 9) binds with LDLR and is internalized into the endosome, similar to LDL. In an acidic endosome, LDLR fails to disassociate from PCSK9, and both proteins are degraded in the lysosome. PCSK9 inhibitors are widely used for treating hypercholesterolemia. However, how PCSK9 diverts LDLR to the lysosome for degradation remains elusive. Some patients are resistant to PCSK9 inhibitors, for unknown reasons. METHODS: Both in vitro and in vivo approaches were used to investigate the molecular and cellular mechanisms of PCSK9-mediated LDLR degradation. LDLR containing FH sequence variations was expressed in Ldlr knockout mice and knockout HuH7 cells to evaluate their response to PCSK9 and PCSK9 inhibitors. RESULTS: Acidic pH induces a conformational change in LDLR extracellular domain and promotes its interaction with SNX17 (sorting nexin 17) through the intracellular domain. Knocking down SNX17 abolishes LDLR recycling and causes accelerated degradation in the lysosome. PCSK9 prevents the acidic pH-induced conformational change in LDLR and blocks its interaction with SNX17. Knocking down SNX17 abolishes PCSK9-mediated LDLR degradation. Any FH sequence variations that disrupt LDLR recycling are unresponsive to PCSK9 or PCSK9 inhibitors, even though they can internalize LDL. CONCLUSIONS: PCSK9 promotes LDLR degradation by preventing SNX17-mediated LDLR recycling. Patients with sequence variations in FH leading to defects in LDLR recycling are resistant to PCSK9 inhibitors. Genetic diagnosis and alternative drugs independent of LDLR will be needed for treatment of these patients.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Guan Y, Liu X, Yang Z, et al. PCSK9 Promotes LDLR Degradation by Preventing SNX17-Mediated LDLR Recycling. Circulation. 2025. PMID: 40071387. doi:10.1161/CIRCULATIONAHA.124.072336

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。